Takeda Accused In U.S. Court Suit Hiding Actos Cancer Risk For Years
This article was originally published in PharmAsia News
Executive Summary
Takeda Pharmaceutical was accused at the end of the first of more than 3,000 U.S. court trials of hiding the risks of bladder cancer associated with its Actos (pioglitazone) diabetes drug.
Takeda Pharmaceutical was accused at the end of the first of more than 3,000 U.S. court trials of hiding the risks of bladder cancer associated with its Actos (pioglitazone) diabetes drug. A lawyer for the plaintiff said in closing arguments Takeda knew of the risk during clinical trials in 2004, but never revealed it because the drug was worth more than $1.6 billion in annual sales. Takeda's own lawyers are expected to make their own closing arguments before the jury begins deliberating. (Click here for more
)
"Takeda's Actos Diabetes Drug Tied To Cancer, Jury Is Told" - Bloomberg (U.S.) (4/15/2013)